Liver Disease Raises Osteoarthritis Risk by 204 Percent
People diagnosed with liver cirrhosis face a 204.8 percent higher risk of developing osteoarthritis compared to the general population, according to epidemiological data from South Korea and the United States.
How Impaired Liver Function Destroys Cartilage
The study reveals that chronic liver disease shuts down the normal delivery network for selenium, an essential trace mineral required for cellular antioxidant defense. In healthy individuals, the liver produces a specialized protein called SELENOP, which transports selenium through the bloodstream to various tissues, including joint cartilage. When the liver becomes diseased, production of SELENOP drops sharply. Without this protein carrier, selenium levels in cartilage plummet, leaving joint cells vulnerable to accumulating reactive oxygen species and premature aging.
Chronic liver disease patients exhibit an increased risk of osteoarthritis regardless of whether the underlying cause is non-alcoholic fatty liver disease or chronic viral hepatitis. Animal models using mice with acute and severe liver damage confirmed that this biochemical disruption leads directly to heavy cartilage destruction and synovial inflammation.
Restoring Selenium via Dietary Intervention
Providing inorganic selenium through drinking water restored antioxidant selenoprotein levels in the joint cartilage of mice with liver damage, even though the underlying liver condition itself did not heal. This targeted dietary supplementation successfully alleviated cartilage destruction, reduced cellular aging, and eased joint pain in the experimental models. The research team emphasizes that bypassing the damaged liver-cartilage axis through direct nutritional replenishment offers a viable strategy for preventing joint degradation in liver patients.
While population data links liver disease and selenium intake to joint health, researchers caution that these observational insights do not yet prove that taking selenium supplements will prevent or treat osteoarthritis in humans. Animal findings cannot be directly extrapolated to human clinical care without rigorous trials to establish safe dosages, long-term safety, and actual therapeutic efficacy. Because excess selenium is toxic, medical professionals warn patients against starting unverified supplementation independently.
Frequently Asked Questions About the Liver-Cartilage Axis
What specific journal published the liver and osteoarthritis study?
The research paper appears in the international journal Cell Metabolism, with an impact factor of 37.0.
Does a diagnosis of fatty liver disease carry the same joint risk as viral hepatitis?
Yes, chronic liver disease patients show a consistently elevated risk of osteoarthritis regardless of whether the root cause is non-alcoholic fatty liver disease or chronic viral hepatitis.
Keep reading